WO2011083391A3 - Biomarkers for anti - igf - 1r cancer therapy - Google Patents

Biomarkers for anti - igf - 1r cancer therapy Download PDF

Info

Publication number
WO2011083391A3
WO2011083391A3 PCT/IB2010/056071 IB2010056071W WO2011083391A3 WO 2011083391 A3 WO2011083391 A3 WO 2011083391A3 IB 2010056071 W IB2010056071 W IB 2010056071W WO 2011083391 A3 WO2011083391 A3 WO 2011083391A3
Authority
WO
WIPO (PCT)
Prior art keywords
igf
biomarkers
cancer therapy
therapy
cancer
Prior art date
Application number
PCT/IB2010/056071
Other languages
French (fr)
Other versions
WO2011083391A2 (en
Inventor
Stephanie Janet Green
Antonio Gualberto
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of WO2011083391A2 publication Critical patent/WO2011083391A2/en
Publication of WO2011083391A3 publication Critical patent/WO2011083391A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present invention relates to use of free IGF-1 and the ratio of insulin/IGFBP in the blood as biomarkers for IGF-1 R antagonist therapy for cancer and to method for treating cancer with an IGF-1 R therapy in patients selected based on such biomarkers.
PCT/IB2010/056071 2010-01-05 2010-12-24 Biomarkers for anti-igf-ir cancer therapy WO2011083391A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29247110P 2010-01-05 2010-01-05
US61/292,471 2010-01-05

Publications (2)

Publication Number Publication Date
WO2011083391A2 WO2011083391A2 (en) 2011-07-14
WO2011083391A3 true WO2011083391A3 (en) 2011-09-01

Family

ID=43920382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/056071 WO2011083391A2 (en) 2010-01-05 2010-12-24 Biomarkers for anti-igf-ir cancer therapy

Country Status (2)

Country Link
JP (1) JP2011141279A (en)
WO (1) WO2011083391A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013008833A (en) 2011-02-02 2013-12-06 Amgen Inc Methods and compositons relating to inhibition of igf-1r.
JPWO2023276869A1 (en) * 2021-06-28 2023-01-05

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
US20050214826A1 (en) * 2004-02-19 2005-09-29 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2007141626A1 (en) * 2006-06-02 2007-12-13 Pfizer Products Inc. Circulating tumor cell assay

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037777A1 (en) 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
KR100983997B1 (en) 2001-01-09 2010-09-28 메르크 파텐트 게엠베하 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
PT1461359E (en) 2002-01-18 2007-06-29 Pf Medicament Novel anti-igf-ir antibodies and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
SE0203746D0 (en) 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
US7378503B2 (en) 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (en) 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
ATE433979T1 (en) 2004-04-02 2009-07-15 Osi Pharm Inc HETEROBICYCLIC PROTEIN KINASE INHIBITORS SUBSTITUTED WITH A 6,6-BICYCLIC RING
US20060153808A1 (en) 2004-11-17 2006-07-13 Board Of Regents, The Universtiy Of Texas System Cancer immunotherapy incorporating p53
CA2590110C (en) 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
EP1896030A1 (en) 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
US8324194B2 (en) 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
BRPI0709843A2 (en) 2006-03-28 2011-07-26 Biogen Idec Inc anti-igf-1r antibodies and uses thereof
JP5185930B2 (en) 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー Pyrrolotriazine kinase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
US20050214826A1 (en) * 2004-02-19 2005-09-29 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2007141626A1 (en) * 2006-06-02 2007-12-13 Pfizer Products Inc. Circulating tumor cell assay

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUALBERTO A. ET AL.: "1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transition", EUR. J. CANCER SUPPLEMENTS, vol. 7, no. 2, September 2009 (2009-09-01), pages 88 - 89, XP026560258 *
GUALBERTO A. ET AL.: "Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions", ONCOGENE, vol. 28, no. 34, 27 August 2009 (2009-08-27), pages 3009 - 3021, XP002636347 *
GUALBERTO A. ET AL.: "Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab", BRIT. J. CANCER, vol. 104, no. 1, 4 January 2011 (2011-01-04), pages 68 - 74, XP002636348 *
KARP D.D. ET AL.: "Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer", J. CLIN. ONCOL., vol. 27, no. 15, 20 May 2009 (2009-05-20), pages 2516 - 2522, XP002636346 *
KARP D.D. ET AL.: "Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin", J. THORAC. ONCOL., vol. 4, no. 11, November 2009 (2009-11-01), pages 1397 - 1403, XP002636345 *

Also Published As

Publication number Publication date
JP2011141279A (en) 2011-07-21
WO2011083391A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
GB201020860D0 (en) Disulfiram formulation and uses thereof
WO2013186240A3 (en) Exendin-4 peptide analogues
EP2692366A4 (en) Medical instrument with slidable coating layer, and syringe
EP3052131A4 (en) Methods for treating cancer in patients with elevated levels of bim
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
EP2563426A4 (en) High shear application in medical therapy
BR112012026707A2 (en) use of an afucosylated anti-cd20 antibody, composition comprising an afucosylated anti-cd20 antibody and method of treating cancer patients by administering an afucosylated anti-cd20 antibody
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
BR112013002441A2 (en) Use of an Afucosylated Anti-cd20 Antibody, Composition and Method of Treatment of a Cancer Patient
HK1185808A1 (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
MX2014010940A (en) The use of antithrombin in the treatment of pre-eclampsia.
MX2013006319A (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer.
EP3016607A4 (en) Systems and methods for in vivo irradiation of blood
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
IL207722A (en) Pyridopyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
GB201223025D0 (en) Prediction of the treatment response to an anti-EGFR molecule in colorectal cancer patients
WO2012082821A3 (en) Melanoma treatments
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2011083391A3 (en) Biomarkers for anti - igf - 1r cancer therapy
WO2011163512A3 (en) Cancer therapy
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10816423

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10816423

Country of ref document: EP

Kind code of ref document: A2